Short palate, lung, and nasal epithelial clone 1 has antimicrobial and antibiofilm activities against the Burkholderia cepacia complex

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 10, 2016, Pages 6003-6012

  Ahmad, Saira ^a   Tyrrell, Jean ^a   Walton, William G ^b   Tripathy, Ashutosh ^c   Redinbo, Matthew R ^b   Tarran, Robert ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b The University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; LEUKOCYTE ELASTASE; SHORT PALATE LUNG AND NASAL EPITHELIAL CLONE 1 PROTEIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BPIFA1 PROTEIN, HUMAN; GLYCOPROTEIN; PHOSPHOPROTEIN; PROTEIN BINDING; RECOMBINANT PROTEIN;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIOSTASIS; BACTERIUM ADHERENCE; BACTERIUM ISOLATE; BIOFILM; BURKHOLDERIA CEPACIA COMPLEX; CONTROLLED STUDY; CYSTIC FIBROSIS; IC50; NEUTROPHILIA; NONHUMAN; PHARYNX; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN SECRETION; UPPER RESPIRATORY TRACT; BINDING SITE; CHEMISTRY; DRUG EFFECTS; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MOLECULAR CLONING; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BINDING SITES; BIOFILMS; BURKHOLDERIA CEPACIA COMPLEX; CLONING, MOLECULAR; ESCHERICHIA COLI; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; LEUKOCYTE ELASTASE; MICROBIAL SENSITIVITY TESTS; PHOSPHOPROTEINS; PROTEIN BINDING; PROTEIN CONFORMATION, ALPHA-HELICAL; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84992571551     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00975-16     Document Type: Article

References (64)

1. Mahenthiralingam E, Baldwin A, Vandamme P. 2002. Burkholderia cepacia complex infection in patients with cystic fibrosis. J Med Microbiol 51:533-538. http://dx.doi.org/10.1099/0022-1317-51-7-533.
2. Vanlaere E, Lipuma JJ, Baldwin A, Henry D, De Brandt E, Mahenthiralingam E, Speert D, Dowson C, Vandamme P. 2008. Burkholderia latens sp. nov., Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov. and Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia complex. Int J Syst Evol Microbiol 58:1580-1590. http://dx.doi.org/10.1099/ijs.0.65634-0.
3. Dedeckova K, Fila L, Skalicka V, Bartosova J, Kucerova T, Vavrova V, Zemkova D, Kalferstova L, Melter O, Cinek O, Drevinek P. 2012. PCR detection of Burkholderia cepacia complex as one of key factors to handle a long-term outbreak. J Cyst Fibros 11:440-445. http://dx.doi.org/10.1016/j.jcf.2012.04.005.
4. Saldias MS, Valvano MA. 2009. Interactions of Burkholderia cenocepacia and other Burkholderia cepacia complex bacteria with epithelial and phagocytic cells. Microbiology 155:2809-2817. http://dx.doi.org/10.1099/mic.0.031344-0.
5. Loutet SA, Valvano MA. 2010. A decade of Burkholderia cenocepacia virulence determinant research. Infect Immun 78:4088-4100. http://dx.doi.org/10.1128/IAI.00212-10.
6. Amin R, Lam M, Dupuis A, Ratjen F. 2011. The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis. Pediatr Pulmonol 46:554-558. http://dx.doi.org/10.1002/ppul.21417.
7. Coutinho CP, Dos Santos SC, Madeira A, Mira NP, Moreira AS, Sa-Correia I. 2011. Long-term colonization of the cystic fibrosis lung by Burkholderia cepacia complex bacteria: epidemiology, clonal variation, and genome-wide expression alterations. Front Cell Infect Microbiol 1:12. http://dx.doi.org/10.3389/fcimb.2011.00012.
8. Mahenthiralingam E, Urban TA, Goldberg JB. 2005. The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol 3:144-156. http://dx.doi.org/10.1038/nrmicro1085.
9. Isles A, Maclusky I, Corey M, Gold R, Prober C, Fleming P, Levison H. 1984. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 104:206-210. http://dx.doi.org/10.1016/S0022-3476(84)80993-2.
10. Valvano MA, Keith KE, Cardona ST. 2005. Survival and persistence of opportunistic Burkholderia species in host cells. Curr Opin Microbiol 8:99-105. http://dx.doi.org/10.1016/j.mib.2004.12.002.
11. Nzula S, Vandamme P, Govan JR. 2002. Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. J Antimicrob Chemother 50:265-269. http://dx.doi.org/10.1093/jac/dkf137.
12. Sousa SA, Ramos CG, Almeida F, Meirinhos-Soares L, Wopperer J, Schwager S, Eberl L, Leitao JH. 2008. Burkholderia cenocepacia J2315 acyl carrier protein: a potential target for antimicrobials' development? Microb Pathog 45:331-336. http://dx.doi.org/10.1016/j.micpath.2008.08.002.
13. Leitao JH, Sousa SA, Cunha MV, Salgado MJ, Melo-Cristino J, Barreto MC, Sa-Correia I. 2008. Variation of the antimicrobial susceptibility profiles of Burkholderia cepacia complex clonal isolates obtained from chronically infected cystic fibrosis patients: a five-year survey in the major Portuguese treatment center. Eur J Clin Microbiol Infect Dis 27:1101-1111. http://dx.doi.org/10.1007/s10096-008-0552-0.
14. Burns JL, Jonas M, Chi EY, Clark DK, Berger A, Griffith A. 1996. Invasion of respiratory epithelial cells by Burkholderia (Pseudomonas) cepacia. Infect Immun 64:4054-4059.
15. Martin DW, Mohr CD. 2000. Invasion and intracellular survival of Burkholderia cepacia. Infect Immun 68:24-29. http://dx.doi.org/10.1128/IAI.68.1.24-29.2000.
16. Schwab U, Abdullah LH, Perlmutt OS, Albert D, Davis CW, Arnold RR, Yankaskas JR, Gilligan P, Neubauer H, Randell SH, Boucher RC. 2014. Localization of Burkholderia cepacia complex bacteria in cystic fibrosis lungs and interactions with Pseudomonas aeruginosa in hypoxic mucus. Infect Immun 82:4729-4745. http://dx.doi.org/10.1128/IAI.01876-14.
17. Forier K, Messiaen AS, Raemdonck K, Nelis H, De Smedt S, Demeester J, Coenye T, Braeckmans K. 2014. Probing the size limit for nanomedicine penetration into Burkholderia multivorans and Pseudomonas aeruginosa biofilms. J Control Release 195:21-28. http://dx.doi.org/10.1016/j.jconrel.2014.07.061.
18. Conway BA, Venu V, Speert DP. 2002. Biofilm formation and acyl homoserine lactone production in the Burkholderia cepacia complex. J Bacteriol 184:5678-5685. http://dx.doi.org/10.1128/JB.184.20.5678-5685.2002.
19. Dales L, Ferris W, Vandemheen K, Aaron SD. 2009. Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis. Eur J Clin Microbiol Infect Dis 28:1275-1279. http://dx.doi.org/10.1007/s10096-009-0774-9.
20. Bingle CD, Bingle L. 2000. Characterisation of the human plunc gene, a gene product with an upper airways and nasopharyngeal restricted expression pattern. Biochim Biophys Acta 1493:363-367. http://dx.doi.org/10.1016/S0167-4781(00)00196-2.
21. Gakhar L, Bartlett JA, Penterman J, Mizrachi D, Singh PK, Mallampalli RK, Ramaswamy S, McCray PB, Jr. 2010. PLUNC is a novel airway surfactant protein with anti-biofilm activity. PLoS One 5:e9098. http://dx.doi.org/10.1371/journal.pone.0009098.
22. Sayeed S, Nistico L, St Croix C, Di YP. 2013. Multifunctional role of human SPLUNC1 in Pseudomonas aeruginosa infection. Infect Immun 81:285-291. http://dx.doi.org/10.1128/IAI.00500-12.
23. Bingle L, Barnes FA, Cross SS, Rassl D, Wallace WA, Campos MA, Bingle CD. 2007. Differential epithelial expression of the putative innate immune molecule SPLUNC1 in cystic fibrosis. Respir Res 8:79. http://dx.doi.org/10.1186/1465-9921-8-79.
24. Garcia-Caballero A, Rasmussen JE, Gaillard E, Watson MJ, Olsen JC, Donaldson SH, Stutts MJ, Tarran R. 2009. SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage. Proc Natl Acad Sci U S A 106:11412-11417. http://dx.doi.org/10.1073/pnas.0903609106.
25. Hobbs CA, Blanchard MG, Alijevic O, Tan CD, Kellenberger S, Bencharit S, Cao R, Kesimer M, Walton WG, Henderson AG, Redinbo MR, Stutts MJ, Tarran R. 2013. Identification of the SPLUNC1 ENaC-inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airway epithelial cultures. Am J Physiol Lung Cell Mol Physiol 305:L990-L1001. http://dx.doi.org/10.1152/ajplung.00103.2013.
26. Liu Y, Di ME, Chu HW, Liu X, Wang L, Wenzel S, Di YP. 2013. Increased susceptibility to pulmonary Pseudomonas infection in Splunc1 knockout mice. J Immunol 191:4259-4268. http://dx.doi.org/10.4049/jimmunol.1202340.
27. Di YP. 2011. Functional roles of SPLUNC1 in the innate immune response against Gram-negative bacteria. Biochem Soc Trans 39:1051-1055. http://dx.doi.org/10.1042/BST0391051.
28. Britto CJ, Liu Q, Curran DR, Patham B, Dela Cruz CS, Cohn L. 2013. Short palate, lung, and nasal epithelial clone-1 is a tightly regulated airway sensor in innate and adaptive immunity. Am J Respir Cell Mol Biol 48: 717-724. http://dx.doi.org/10.1165/rcmb.2012-0072OC.
29. Tarran R, Redinbo MR. 2014. Mammalian short palate lung and nasal epithelial clone 1 (SPLUNC1) in pH-dependent airway hydration. Int J Biochem Cell Biol 52:130-135. http://dx.doi.org/10.1016/j.biocel.2014.03.002.
30. Liu Y, Bartlett JA, Di ME, Bomberger JM, Chan YR, Gakhar L, Mallampalli RK, McCray PB, Jr, Di YP. 2013. SPLUNC1/BPIFA1 contributes to pulmonary host defense against Klebsiella pneumoniae respiratory infection. Am J Pathol 182:1519-1531. http://dx.doi.org/10.1016/j.ajpath.2013.01.050.
31. Jiang D, Wenzel SE, Wu Q, Bowler RP, Schnell C, Chu HW. 2013. Human neutrophil elastase degrades SPLUNC1 and impairs airway epithelial defense against bacteria. PLoS One 8:e64689. http://dx.doi.org/10.1371/journal.pone.0064689.
32. Walton WG, Ahmad S, Little MS, Kim CS, Tyrrell J, Lin Q, Di YP, Tarran R, Redinbo MR. 2016. Structural features essential to the antimicrobial functions of human SPLUNC1. Biochemistry 55:2979-2991. http://dx.doi.org/10.1021/acs.biochem.6b00271.
33. Bals R, Weiner DJ, Wilson JM. 1999. The innate immune system in cystic fibrosis lung disease. J Clin Invest 103:303-307. http://dx.doi.org/10.1172/JCI6277.
34. Hiemstra PS, McCray PB, Jr, Bals R. 2015. The innate immune function of airway epithelial cells in inflammatory lung disease. Eur Respir J 45: 1150-1162. http://dx.doi.org/10.1183/09031936.00141514.
35. Parker D, Prince A. 2011. Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol 45:189-201. http://dx.doi.org/10.1165/rcmb.2011-0011RT.
36. Elborn JS, Cordon SM, Parker D, Delamere FM, Shale DJ. 1993. The host inflammatory response prior to death in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Respir Med 87:603-607. http://dx.doi.org/10.1016/S0954-6111(05)80263-X.
37. Voynow JA, Fischer BM, Zheng S. 2008. Proteases and cystic fibrosis. Int J Biochem Cell Biol 40:1238-1245. http://dx.doi.org/10.1016/j.biocel.2008.03.003.
38. Richman-Eisenstat J. 1996. Cytokine soup: making sense of inflammation in cystic fibrosis. Pediatr Pulmonol 21:3-5. http://dx.doi.org/10.1002/1099-0496(199601)21:1〈3::AID-PPUL1950210103〉3.0.CO;2-B.
39. Belaaouaj A. 2002. Neutrophil elastase-mediated killing of bacteria: lessons from targeted mutagenesis. Microbes Infect 4:1259-1264. http://dx.doi.org/10.1016/S1286-4579(02)01654-4.
40. Garland AL, Walton WG, Coakley RD, Tan CD, Gilmore RC, Hobbs CA, Tripathy A, Clunes LA, Bencharit S, Stutts MJ, Betts L, Redinbo MR, Tarran R. 2013. Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways. Proc Natl Acad Sci U S A 110:15973-15978. http://dx.doi.org/10.1073/pnas.1311999110.
41. Margolis JJ, El-Etr S, Joubert LM, Moore E, Robison R, Rasley A, Spormann AM, Monack DM. 2010. Contributions of Francisella tularensis subsp. novicida chitinases and Sec secretion system to biofilm formation on chitin. Appl Environ Microbiol 76:596-608. http://dx.doi.org/10.1128/AEM.02037-09.
42. Vandamme P, Holmes B, Coenye T, Goris J, Mahenthiralingam E, LiPuma JJ, Govan JR. 2003. Burkholderia cenocepacia sp. nov. - a new twist to an old story. Res Microbiol 154:91-96. http://dx.doi.org/10.1016/S0923-2508(03)00026-3.
43. Loutet SA, Valvano MA. 2011. Extreme antimicrobial peptide and polymyxin B resistance in the genus Burkholderia. Front Cell Infect Microbiol 1:6. http://dx.doi.org/10.3389/fcimb.2011.00006.
44. Loutet SA, Flannagan RS, Kooi C, Sokol PA, Valvano MA. 2006. A complete lipopolysaccharide inner core oligosaccharide is required for resistance of Burkholderia cenocepacia to antimicrobial peptides and bacterial survival in vivo. J Bacteriol 188:2073-2080. http://dx.doi.org/10.1128/JB.188.6.2073-2080.2006.
45. Conese M, Copreni E, Di Gioia S, De Rinaldis P, Fumarulo R. 2003. Neutrophil recruitment and airway epithelial cell involvement in chronic cystic fibrosis lung disease. J Cyst Fibros 2:129-135. http://dx.doi.org/10.1016/S1569-1993(03)00063-8.
46. Gally F, Di YP, Smith SK, Minor MN, Liu Y, Bratton DL, Frasch SC, Michels NM, Case SR, Chu HW. 2011. SPLUNC1 promotes lung innate defense against Mycoplasma pneumoniae infection in mice. Am J Pathol 178:2159-2167. http://dx.doi.org/10.1016/j.ajpath.2011.01.026.
47. Kawabata K, Suzuki M, Sugitani M, Imaki K, Toda M, Miyamoto T. 1991. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun 177:814-820. http://dx.doi.org/10.1016/0006-291X(91)91862-7.
48. Zhou HD, Li XL, Li GY, Zhou M, Liu HY, Yang YX, Deng T, Ma J, Sheng SR. 2008. Effect of SPLUNC1 protein on the Pseudomonas aeruginosa and Epstein-Barr virus. Mol Cell Biochem 309:191-197. http://dx.doi.org/10.1007/s11010-007-9659-3.
49. Baird RM, Brown H, Smith AW, Watson ML. 1999. Burkholderia cepacia is resistant to the antimicrobial activity of airway epithelial cells. Immunopharmacology 44:267-272. http://dx.doi.org/10.1016/S0162-3109(99)00122-8.
50. Meszaros K, Parent JB, Gazzano-Santoro H, Little R, Horwitz A, Parsons T, Theofan G, Grinna L, Weickmann J, Elsbach P, Weiss J, Conlon PJ. 1993. A recombinant amino terminal fragment of bactericidal/permeability-increasing protein inhibits the induction of leukocyte responses by LPS. J Leukoc Biol 54:558-563.
51. De Soyza A, Silipo A, Lanzetta R, Govan JR, Molinaro A. 2008. Chemical and biological features of Burkholderia cepacia complex lipopolysaccharides. Innate Immun 14:127-144. http://dx.doi.org/10.1177/1753425908093984.
52. Rose H, Baldwin A, Dowson CG, Mahenthiralingam E. 2009. Biocide susceptibility of the Burkholderia cepacia complex. J Antimicrob Chemother 63:502-510. http://dx.doi.org/10.1093/jac/dkn540.
53. Schutte BC, McCray PB, Jr. 2002. Beta-defensins in lung host defense. Annu Rev Physiol 64:709-748. http://dx.doi.org/10.1146/annurev.physiol.64.081501.134340.
54. Schnapp D, Harris A. 1998. Antibacterial peptides in bronchoalveolar lavage fluid. Am J Respir Cell Mol Biol 19:352-356. http://dx.doi.org/10.1165/ajrcmb.19.3.3384.
55. Konstan MW, Chen PW, Sherman JM, Thomassen MJ, Wood RE, Boat TF. 1981. Human lung lysozyme: sources and properties. Am Rev Respir Dis 123:120-124.
56. Cole AM, Dewan P, Ganz T. 1999. Innate antimicrobial activity of nasal secretions. Infect Immun 67:3267-3275.
57. Kennedy S, Beaudoin T, Yau YC, Caraher E, Zlosnik JE, Speert DP, LiPuma JJ, Tullis E, Waters V. 2016. Activity of tobramycin against cystic fibrosis isolates of Burkholderia cepacia complex grown as biofilms. Antimicrob Agents Chemother 60:348-355. http://dx.doi.org/10.1128/AAC.02068-15.
58. Silva IN, Tavares AC, Ferreira AS, Moreira LM. 2013. Stress conditions triggering mucoid morphotype variation in Burkholderia species and effect on virulence in Galleria mellonella and biofilm formation in vitro. PLoS One 8:e82522. http://dx.doi.org/10.1371/journal.pone.0082522.
59. Al-Bakri AG, Gilbert P, Allison DG. 2005. Influence of gentamicin and tobramycin on binary biofilm formation by co-cultures of Burkholderia cepacia and Pseudomonas aeruginosa. J Basic Microbiol 45:392-396. http://dx.doi.org/10.1002/jobm.200510011.
60. Splendiani A, Livingston AG, Nicolella C. 2006. Control of membrane-attached biofilms using surfactants. Biotechnol Bioeng 94:15-23. http://dx.doi.org/10.1002/bit.20752.
61. Jiang D, Persinger R, Wu Q, Gross A, Chu HW. 2013. α1-Antitrypsin promotes SPLUNC1-mediated lung defense against Pseudomonas aeruginosa infection in mice. Respir Res 14:122. http://dx.doi.org/10.1186/1465-9921-14-122.
62. Drevinek P, Mahenthiralingam E. 2010. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect 16:821-830. http://dx.doi.org/10.1111/j.1469-0691.2010.03237.x.
63. Saiman L, Siegel J, Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. 2003. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 31:S1-S62.
64. Courtney JM, Dunbar KE, McDowell A, Moore JE, Warke TJ, Stevenson M, Elborn JS. 2004. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 3:93-98. http://dx.doi.org/10.1016/j.jcf.2004.01.005.